Pipeline news

• Syndax Announces Pricing of Public Offering of Common Stock

  09 December 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of 5,434,783 shares of its common stock at a price to the public of  $23.00  per share.

• Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock

  08 December 2020

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering of 5 million shares of its common stock for gross proceeds of $70 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Marinus.

• Marinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock

  07 December 2020

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Marinus. Marinus has granted the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares offered in the public offering.

• Syndax Announces Proposed Public Offering of Common Stock

  07 December 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. 

• Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD

  06 December 2020

  

  Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated data from the Company's Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with chronic graft versus host disease (cGVHD). The data will be featured today during an oral presentation at the 62nd  American Society of Hematology  (ASH) Annual Meeting and Exposition. 

• Epic Sciences Enters into Exclusive Licensing Agreement and Collaboration with USC Michelson Center to Advance Next-Generation Liquid Biopsy Technology for Precision Oncology

  19 November 2020

  

  Epic Sciences, Inc. today announced it has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience. Dr. Kuhn is a founding member of the USC Michelson Center and leads USC’s Convergent Science Institute in Cancer (CSI-Cancer). The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells (CTCs), which Epic is developing into liquid-biopsy diagnostics used for characterizing a patient’s cancer to guide treatment decisions.

• Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update

  11 November 2020

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update on key initiatives.

• Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan

  06 November 2020

  

  Atea Pharmaceuticals, Inc.  (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of itsAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the appointment of Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee. common stock at a price to the public of  $24.00  per share.

• Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update

  02 November 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended  September 30, 2020 . In addition, the Company provided a clinical and business update.

• Atea Pharmaceuticals Announces Pricing of Initial Public Offering

  29 October 2020

  

  Atea Pharmaceuticals, Inc.  (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a price to the public of  $24.00  per share.